



PRESCRIPTION DRUG
MEDICATION REQUEST FORM
FAX TO 1-866-240-8123

DUPIXENT PRIOR AUTHORIZATION FORM
PATIENT INFORMATION

Subscriber ID Number		Group Number	
Patient Name	Patient Telephone Number	Date of Birth	
Patient Address	City	State	Zip Code

PRESCRIBER INFORMATION

Physician Name	Phone	Fax	
Physician Address	City	State	Zip Code
Suite / Building	Physician Signature	Date	

MEDICATION INFORMATION

Requested Drug Strength:	<input type="checkbox"/> 200mg/1.14mL	<input type="checkbox"/> 300mg/2mL	Number of pens/syringes per Month
--------------------------	---------------------------------------	------------------------------------	--

Diagnosis:

CLINICAL CRITERIA

If Dupixent is being used to treat **atopic dermatitis**, please answer the following:

- Dupixent is being prescribed by a:
 Dermatologist Allergist Immunologist Other: _____
- Does the patient have atopic dermatitis with facial or anogenital involvement?
 Yes No
- Has the patient experienced therapeutic failure, intolerance, or contraindication to any of the following?
Please select **ALL** that apply:
 A topical corticosteroid (e.g. Betamethasone, Clobetasol, Triamcinolone, etc.)
 Topical Tacrolimus (Protopic)
 Topical Pimecrolimus (Elidel)
- Does the patient require induction dosing of 4 pens/syringes for the first 4 weeks of therapy?
 Yes No
- Is this a request for reauthorization?
 Yes No
 - If **YES**, has the patient experienced positive clinical response?
 Yes No

If Dupixent is being used to treat **moderate-to-severe asthma**, please answer the following:

1. Please provide all of the following:
 - a. Patient's pretreatment forced expiratory volume in one second (FEV₁): _____% predicted
 - b. Patient's FEV₁ reversibility after albuterol (salbutamol) administration: _____%
 - c. Blood eosinophil count: _____cells/mcL
2. Is the patient currently taking daily or alternate-day oral corticosteroids?
 Yes No
3. Is the patient using a medium- or high-dose inhaled corticosteroid?
 Yes No
4. Is the patient using a long-acting beta agonist?
 Yes No
5. Does the patient require induction dosing of 4 pens/syringes for the first 4 weeks of therapy?
 Yes No
6. Is this a request for reauthorization?
 Yes No
 - a. If **YES**, please select **ALL** that apply:
 - Patient has demonstrated improvement or stability
 - Patient has decreased rescue medication or oral corticosteroid use
 - Patient had a decrease in frequency of severe asthma exacerbations
 - Patient had an increase in pulmonary function from baseline (e.g. FEV₁)
 - Patient had a reduction in reported asthma-related symptoms (e.g. asthmatic symptoms upon awakening, coughing, fatigue, shortness of breath, sleep disturbance, or wheezing)

If Dupixent is being used to treat **chronic rhinosinusitis with nasal polyposis**, please answer the following:

1. Please provide:
 - a. Patient's baseline bilateral nasal polyp score (**from 0 to 8**): _____
*The Nasal Polyp Score is used to characterize the patient's polyps (sum of the left and right nostril scores).
0 = no polyps
8 = severe disease with large polyps causing complete obstruction of the inferior nasal cavity*
 - b. Patient's baseline nasal congestion score (**from 0 to 3**): _____
*The Nasal Congestion Score is a tool used to measure changes in nasal congestion and obstruction.
0 = no symptoms
3 = severe symptoms*
2. Has the patient experienced therapeutic failure, intolerance, or contraindication to the following:
Please select **ALL** that apply:
 - An intranasal corticosteroid
 - A 14-day course of oral corticosteroids
3. Is this a request for reauthorization?
 Yes No
 - a. If **YES**, please select **ALL** that apply:
 - Patient is responding to therapy
 - Patient has a decrease in their nasal polyp score
 - Patient has a reduction in their nasal congestion/obstruction severity score

INSTRUCTIONS FOR COMPLETING THIS FORM

1. Submit a separate form for each medication.
2. Complete **ALL** information on the form.
NOTE: *The prescribing physician (PCP or Specialist) should, in most cases, complete the form.*
3. Please provide the physician address as it is required for physician notification.
4. Fax the **completed** form and all clinical documentation to **1-866-240-8123**

This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association. Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.